DVA

Business profile & competitive position

DaVita Inc. (DVA) is classified in the Healthcare sector under the Medical - Care Facilities industry, and it operates as one of the largest U.S. providers of kidney dialysis services and related laboratory services for patients with chronic kidney failure and end-stage kidney disease. As of December 31, 2025, DaVita ran 2,657 outpatient U.S. dialysis centers serving approximately 200,500 patients. The company also operates integrated kidney care, ancillary services, and an international dialysis business spanning outpatient hemodialysis, hospital inpatient dialysis, home-based dialysis, and kidney-transplant support.

U.S. dialysis revenues represented approximately 86% of consolidated revenues, and the filing emphasizes that nearly all non-hospital dialysis profits came from commercial payors. That concentration means commercial insurance pricing and mix are central to profitability. DaVita has been an industry leader in CMS’s Quality Incentive Program for the 11 most recently reported years and in the Five-Star Quality Rating System for the 10 most recently reported years. Those quality rankings are a tangible operational credential, but they do not guarantee pricing power. The 6.0% net margin is consistent with a capital-intensive, regulated services model, while the -123.6% ROE indicates a heavily leveraged or negative-shareholder-equity capital structure rather than an expansive equity-return business. In short, scale and quality are clear; the margin profile and negative ROE suggest the economics are constrained by reimbursement rules and capital deployment, not by an unregulated moat.

Financial posture

DaVita currently carries an $11.9 billion market cap, trades at a trailing P/E of 16.1, and has a beta of 0.80. The P/E sits in a middle band for healthcare services, neither deeply discounted nor richly valued. The 0.80 beta implies the stock has historically moved less than the broader market, which fits a provider whose cash flows are tied to recurring dialysis treatments.

The profitability picture is split. The 6.0% net margin shows the company converts sales into profit, but the -123.6% ROE is extreme and signals either negative shareholders’ equity or a loss period layered on top of a thin capital base. With a positive net margin and negative ROE, DaVita is almost certainly running with significant leverage or balance-sheet liabilities relative to book equity. That structure can amplify returns but also magnifies risk if reimbursement or interest-rate conditions shift. The data supplied does not include gross, operating, or debt figures, so any deeper leverage conclusion would require those additional line items.

Strategic priorities & outlook

DaVita’s most recent 10-K frames its near-term operational focus around three themes. First, it aims to reimagine high-quality kidney care to be more preventative, better integrated, outcome-focused, lower-cost, and personalized at scale. Second, it wants to build integrated care capabilities that coordinate services across the renal care continuum, from chronic kidney disease to end-stage kidney disease to kidney transplant. Third, it is working to support the Comprehensive Kidney Care Contracting (CKCC) model goals of delaying disease progression, promoting home dialysis where appropriate, and incentivizing transplants.

These priorities align with CMS’s move toward value-based kidney care. Home dialysis growth and transplant coordination are recurring strategic targets because they can reduce total cost of care, but they also depend on patient selection, reimbursement, and clinical infrastructure. Internationally, DaVita had 585 outpatient dialysis centers across 14 countries serving approximately 94,500 patients as of December 31, 2025. That footprint adds diversification but remains a smaller contributor than the U.S. core.

Macro & geopolitical exposure

As a Medical - Care Facilities operator, DaVita is exposed to the reimbursement environment first and foremost. CMS payment rules for end-stage renal disease, the Quality Incentive Program, the Five-Star Quality Rating System, and the Comprehensive Kidney Care Contracting model directly affect revenue and margin. Changes to Medicare, Medicaid, or commercial insurer rates can move the business quickly because dialysis is a recurring, high-volume service with limited short-term demand elasticity.

Labor markets also matter: dialysis centers require specialized nurses, technicians, and clinical staff, so wage inflation and staffing shortages are industry-wide pressure points. Supply-chain matters include dialyzers, replacement fluids, and pharmaceuticals. Although the U.S. dialysis business dominates results, the international segment across 14 countries introduces currency translation risk, foreign regulation, and local healthcare-policy changes. Broader healthcare reform, drug-pricing legislation, and immigration or trade policy that affects medical-equipment imports are relevant macro vectors, even though the company does not make drugs or devices itself.

Recent developments

The most recent news flow heading into the October 28 report included:

• October 19, 2026 (PR Newswire): DaVita scheduled its third-quarter 2026 investor conference call.
• October 18, 2026 (DefenseWorld.net): Counterpoint Mutual Funds LLC acquired 18,685 shares of DaVita common stock.
• October 15, 2026 (PR Newswire): DaVita brought new clinical research to ASN Kidney Week 2026, highlighting evidence for the next era of kidney care.
• October 9, 2026 (Zacks): A headline explored why DaVita outpaced the stock market that day.

The October 15 research presentation is a reminder that the company is positioning itself around next-generation kidney care, but research presentations at ASN Kidney Week do not, on their own, translate into near-term earnings. The October 18 institutional purchase is a data point of fund interest; it is not a directional signal by itself. With the stock at $187, an RSI of 57.1, and the 50-day EMA at $185.68, price action is hovering near its short-term moving average heading into the upcoming release.

Earnings behavior & post-earnings drift

Over the last eight reported quarters, DaVita has beaten earnings expectations 6 out of 8 times, for a 75% beat rate, with an average earnings surprise of +2.3%. The average 5-day price move in the five trading days after earnings over those quarters is +6.36%, classified as an upward drift. On the surface, that looks like a beat-biased stock with positive post-earnings momentum.

The last four quarters, however, show a more complicated pattern. In August 2026, DaVita reported EPS of $4.02 against a consensus of $3.88—a 3.6% beat—yet the stock fell 17.24% the next day and 21.78% over the following five days. That is a sharp disconnect from the headline beat. By contrast, in May 2026 the company earned $2.87 versus an estimate of $2.41, a 19.1% beat, and the stock rose 23.46% the next day and 27.7% over five days. In February 2026, EPS of $3.40 beat the $3.24 estimate by 4.9%, driving a 21.17% one-day gain and a 23.79% five-day gain. The only miss in this window came in October 2025, when EPS of $2.51 missed the $3.17 estimate by 20.8%, and the stock fell 6.17% the next day and 4.27% over five days.

The takeaway is that the average positive drift is driven by large gains on a few beats, while the August 2026 quarter proves that a beat can be overwhelmed by guidance, reimbursement concerns, or commercial-payor commentary. For the upcoming October 28, 2026 (after close) report, the consensus EPS estimate is $3.57. The history shows that the market’s real expectation may not be captured by the estimate alone; the reaction often hinges on the surrounding narrative and outlook.

For a deeper dive into how sell-side and institutional analysts are interpreting these same figures ahead of the October 28 report, consider reviewing the full institutional verdict and consensus commentary on the trading-analysis platform.